Related references
Note: Only part of the references are listed.MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer
Ofra Novoplansky et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Differential Activation of ERK Signaling in HPV-Related Oropharyngeal Squamous Cell Carcinoma
Chao Rong et al.
CANCERS (2019)
NCCN Guidelines® Insights Head and Neck Cancers, Version 1.2018 Featured Updates to the NCCN Guidelines
A. Dimitrios Colevas et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Knockdown of Annexin A1 Enhances Radioresistance and Inhibits Apoptosis in Nasopharyngeal Carcinoma
Li Liao et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2018)
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Ben Zhao et al.
ONCOTARGET (2017)
Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Athanassios Argiris et al.
FRONTIERS IN ONCOLOGY (2017)
Targeting irradiation-induced mitogen-activated protein kinase activation in vitro and in an ex vivo model for human head and neck cancer
Annette Affolter et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma
Paolo Bossi et al.
ONCOTARGET (2016)
Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway
Pengfei Ma et al.
THERANOSTICS (2016)
Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma
Dominik Horn et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2015)
MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma
Li Ren Kong et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Loss of SOX2 expression induces cell motility via vimentin up-regulation and is an unfavorable risk factor for survival of head and neck squamous cell carcinoma
Pilar Bayo et al.
MOLECULAR ONCOLOGY (2015)
ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap
Tauno Metsalu et al.
NUCLEIC ACIDS RESEARCH (2015)
Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition
Irene Caffa et al.
ONCOTARGET (2015)
Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)
Roger B. Cohen
CANCER TREATMENT REVIEWS (2014)
Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303
Amanda Psyrri et al.
CLINICAL CANCER RESEARCH (2014)
RAS/PI3K Crosstalk and Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma
T. Rampias et al.
CLINICAL CANCER RESEARCH (2014)
Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution
Sandra Misale et al.
CANCER DISCOVERY (2014)
Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway
Alexis B. Cortot et al.
CANCER RESEARCH (2013)
A Poor Prognosis Subtype of HNSCC Is Consistently Observed across Methylome, Transcriptome, and miRNome Analysis
Alain C. Jung et al.
CLINICAL CANCER RESEARCH (2013)
Increased radioresistance via G12S K-Ras by compensatory upregulation of MAPK and PI3K pathways in epithelial cancer
Annette Affolter et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2013)
Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance
Carolien Boeckx et al.
ONCOLOGIST (2013)
SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival Analysis
Raul Aguirre-Gamboa et al.
PLOS ONE (2013)
Viral RNA Patterns and High Viral Load Reliably Define Oropharynx Carcinomas with Active HPV16 Involvement
Dana Holzinger et al.
CANCER RESEARCH (2012)
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
Ryan B. Corcoran et al.
CANCER DISCOVERY (2012)
Gene Expression Profiling Predicts the Development of Oral Cancer
Pierre Saintigny et al.
CANCER PREVENTION RESEARCH (2011)
Management of Recurrent Head and Neck Cancer Recent Progress and Future Directions
Bruce E. Brockstein
DRUGS (2011)
ACTIVATION OF MITOGEN-ACTIVATED PROTEIN KINASE EXTRACELLULAR SIGNAL-RELATED KINASE IN HEAD AND NECK SQUAMOUS CELL CARCINOMAS AFTER IRRADIATION AS PART OF A RESCUE MECHANISM
Annette Affolter et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2011)
Aberrant expression of p53, p16INK4a and Ki-67 as basic biomarker for malignant progression of oral leukoplakias
Wasim Nasser et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2011)
Disease control and functional outcome in three modern combined organ preserving regimens for locally advanced squamous cell carcinoma of the head and neck (SCCHN)
Alexandra D. Jensen et al.
RADIATION ONCOLOGY (2011)
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
Kimio Yonesaka et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck (SCCHN) in the elderly and multi-morbid patient: a single-centre experience
Alexandra D. Jensen et al.
HEAD & NECK ONCOLOGY (2010)
Dysregulated molecular networks in head and neck carcinogenesis
Alfredo A. Molinolo et al.
ORAL ONCOLOGY (2009)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC)
R. Hitt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Comparison of p16INK4a expression with p53 alterations in head and neck cancer by tissue microarray analysis
S. Karsai et al.
JOURNAL OF PATHOLOGY (2007)
Counting colonies of clonogenic assays by using densitometric software
Maximilian Niyazi et al.
RADIATION ONCOLOGY (2007)
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy
Jan B. Vermorken et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Epidermal growth factor receptor biology in head and neck cancer
Shailaja Kalyankrishna et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib
N Normanno et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Epidermal growth factor receptor (EGFR) signaling in cancer
N Normanno et al.
GENE (2006)
Clonogenic assay of cells in vitro
Nicolaas A. P. Franken et al.
NATURE PROTOCOLS (2006)